Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Annovis BioScancellAmpliphi BiosciencesRedx PharmaOncolytics Biotech
SymbolNYSE:ANVSLON:SCLPNYSEAMERICAN:APHBLON:REDXTSE:ONC
Price Information
Current Price$21.72GBX 23$4.17GBX 65C$3.77
52 Week RangeN/AN/AN/AN/ABuy
MarketRank™
Overall Score0.00.60.60.61.2
Analysis Score0.00.00.00.03.3
Community Score0.03.02.82.92.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/ABuy
Consensus Price TargetN/AN/AN/AN/AC$6.00
% Upside from Price TargetN/AN/AN/AN/A59.15% upside
Trade Information
Market Cap$150.89 million£187.50 million$139.57 million£175.29 millionC$198.94 million
BetaN/AN/AN/AN/AN/A
Average Volume282,1192,494,441842,20029,391299,762
Sales & Book Value
Annual RevenueN/AN/AN/A£5.69 millionN/A
Price / SalesN/AN/AN/A31.32N/A
CashflowN/AGBX 3.55 per shareN/AGBX 14.10 per shareC$0.59 per share
Price / CashN/A6.49N/A4.616.34
Book ValueN/AGBX 3.30 per shareN/AGBX 1.40 per shareC$0.54 per share
Price / BookN/AN/AN/A0.46N/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AGBX (1.40)N/AGBX (5.40)C($0.56)
Trailing P/E Ratio0.00N/A0.00N/AN/A
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A14.26%N/A761.82%1.62%
Current RatioN/A3.99%N/A2.70%12.45%
Quick RatioN/A3.99%N/A2.59%11.56%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees222304025
Shares Outstanding6.95 million815.22 million33.47 million273.89 million52.77 million
Next Earnings Date5/4/2021 (Estimated)N/AN/A6/28/2021 (Estimated)5/14/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Oncolytic Virus Therapy Market Business Scenario, Size, Share, Growth, Insights, Industry Analysis, Trends and Forecasts Report 2027Oncolytic Virus Therapy Market Business Scenario, Size, Share, Growth, Insights, Industry Analysis, Trends and Forecasts Report 2027
sbwire.com - April 15 at 6:07 PM
Heres Why Were Not Too Worried About Oncolytics Biotechs (TSE:ONC) Cash Burn SituationHere's Why We're Not Too Worried About Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
finance.yahoo.com - April 14 at 12:00 PM
Market Analysts see Oncolytics Biotech Inc. [ONCY] gaining to $15. Time to buy?Market Analysts see Oncolytics Biotech Inc. [ONCY] gaining to $15. Time to buy?
dbtnews.com - April 13 at 8:59 PM
Oncolytics Biotechs (ONC) "Outperform" Rating Reiterated at Royal Bank of CanadaOncolytics Biotech's (ONC) "Outperform" Rating Reiterated at Royal Bank of Canada
americanbankingnews.com - April 13 at 12:28 PM
Oncolytics Biotechs Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast CancerOncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer
finance.yahoo.com - April 12 at 1:58 PM
BRIEF-Oncolytics Biotech® Presents Preclinical Data On Pelareorep-Based Combination Therapies At AACR Annual MeetingBRIEF-Oncolytics Biotech® Presents Preclinical Data On Pelareorep-Based Combination Therapies At AACR Annual Meeting
msn.com - April 12 at 8:58 AM
Oncolytics Biotech Inc. (NASDAQ:ONCY) Has Yet To Win Over Analysts?Oncolytics Biotech Inc. (NASDAQ:ONCY) Has Yet To Win Over Analysts?
stocksregister.com - April 12 at 8:58 AM
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual MeetingOncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
finance.yahoo.com - April 12 at 8:58 AM
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 StudyOncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
finance.yahoo.com - April 12 at 8:58 AM
BMS, PsiOxus add an asset to Opdivo-oncolytic virus combo dealBMS, PsiOxus add an asset to Opdivo-oncolytic virus combo deal
fiercebiotech.com - April 9 at 1:08 AM
Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid TumorsOncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors
finance.yahoo.com - April 5 at 8:04 AM
Here’s Why Oncolytics Biotech Inc. (NASDAQ:ONCY) is an Attractive Pick for Investors NowHere’s Why Oncolytics Biotech Inc. (NASDAQ:ONCY) is an Attractive Pick for Investors Now
stocksregister.com - March 29 at 3:17 PM
Oncolytics Biotech (ONCY) Enters Overbought TerritoryOncolytics Biotech (ONCY) Enters Overbought Territory
finance.yahoo.com - March 25 at 1:30 PM
Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual MeetingOncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting
finance.yahoo.com - March 10 at 6:14 PM
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsOncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
finance.yahoo.com - March 5 at 10:13 AM
Oncolytics Bios cancer-killing virus arms CAR-T cells to attack solid tumors in miceOncolytics Bio's cancer-killing virus arms CAR-T cells to attack solid tumors in mice
fiercebiotech.com - February 26 at 8:47 PM
5 Penny Stocks To Watch This Week If Biotech Is Your Focus In February5 Penny Stocks To Watch This Week If Biotech Is Your Focus In February
marketwatch.com - February 24 at 10:57 PM
Oncolytic Virus, CAR T Combination Preclinical Study Shows Activity in Solid TumorsOncolytic Virus, CAR T Combination Preclinical Study Shows Activity in Solid Tumors
ajmc.com - February 24 at 5:56 PM
Benzingas Top Ratings Upgrades, Downgrades For February 17, 2021Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021
finance.yahoo.com - February 17 at 2:31 PM
ONCY Stock Price Increases Over 60% Pre-Market: Why It HappenedONCY Stock Price Increases Over 60% Pre-Market: Why It Happened
pulse2.com - February 17 at 9:30 AM
Oncolytic Virus Immunotherapy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027Oncolytic Virus Immunotherapy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
marketwatch.com - February 12 at 1:42 PM
Metastatic Melanoma Drug Market: COVID-19 Recovery Updates and New Development Strategies 2021-2030Metastatic Melanoma Drug Market: COVID-19 Recovery Updates and New Development Strategies 2021-2030
apnews.com - January 19 at 4:52 PM
Pancreatic Cancer Market Overview, Sales Revenue, Opportunities, Size, Share, Competitive Landscape and Comprehensive Research Study 2024Pancreatic Cancer Market Overview, Sales Revenue, Opportunities, Size, Share, Competitive Landscape and Comprehensive Research Study 2024
marketwatch.com - January 17 at 8:59 AM
Nymi survey reveals the majority of Americans would welcome using a wearable at work, as companies seek technology to plan for safe returns to workplacesNymi survey reveals the majority of Americans would welcome using a wearable at work, as companies seek technology to plan for safe returns to workplaces
finance.yahoo.com - January 13 at 8:55 AM
Top Penny Stocks To Buy According To Analysts With 42%-291% TargetsTop Penny Stocks To Buy According To Analysts With 42%-291% Targets
marketwatch.com - January 8 at 3:49 PM
DateCompanyBrokerageAction
3/26/2019Ampliphi BiosciencesHC WainwrightReiterated Rating
4/13/2021Oncolytics BiotechRoyal Bank of CanadaReiterated Rating
2/24/2021Oncolytics BiotechLeede Jones GabReiterated Rating
1/2/2020Oncolytics BiotechRoth CapitalReiterated Rating
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.